Table 5.
Overview of factors associated with the occurrence of hypersensitivity reactions (HSRs)
| All departments (n = 1332) OR (95% CI) | Departments of internal medicine, gastroenterology, and other b (n = 1143) OR (95% CI) | Department of gynaecology (n = 189) OR (95% CI) | |
|---|---|---|---|
| Age (year) | 0.956 (0.939–0.972)P < 0.0001 | 0.953 (0.936–0.970)P < 0.0001 | 1.002 (0.933–1.076)P > 0.950 |
| Sex | |||
| Male vs . female | 0.245 (0.083–0.719)P = 0.01 | 0.252 (0.086–0.743)P = 0.012 | n.a. |
| Type intravenous iron | |||
| Iron isomaltoside‐1000 vs . ferric carboxymaltose | 3.411 (1.910–6.093)P < 0.0001 | 3.785 (1.964–7.293)P < 0.0001 | 2.031 (0.448–9.219)P = 0.359 |
| Presence of a comorbidity a | |||
| Presence of a comorbidity a | 3.577 (1.899–6.739)P < 0.0001 | 2.775 (1.398–5.512)P = 0.004 | 10.072 (2.404–42.202)P = 0.002 |
| Departments | |||
| Department gastroenterology vs . other b | 0.854 (0.261–2.789)P = 0.794 | 0.897 (0.274–2.944)P = 0.858 | n.a. |
| Department internal medicine vs . other b | 2.424 (0.795–7.394)P = 0.120 | 2.292 (0.751–6.996)P = 0.145 | n.a. |
| Department gynaecology vs . other b | 1.536 (0.447–5.284)P = 0.496 | n.a. | n.a. |
CI, confidence interval; n.a., not applicable; OR, odds ratio; P‐value of <0.0125 indicates statistical significance
a
Comorbidity: registered comorbidities at every administration of intravenous iron. Every comorbidity is counted separately
b
Other includes cardiology, surgery, urology, dermatology, rheumatology, paediatrics, and ophthalmology, and the care hotel located near the hospital